United States Tuberculosis Treatment Market Report and Forecast 2025-2034

The United States tuberculosis treatment market was valued at USD 890.40 Million in 2024, driven by the rising tuberculosis incidence and increased focus on multidrug-resistant tuberculosis management in the region. The market is anticipated to grow at a CAGR of 5.10% during the forecast period of 2025-2034, with the values likely to reach USD 1.46 billion by 2034. The market is driven by the availability of established therapies and government programs supporting treatment access. Advancements in rapid diagnostics and drug formulations offer significant opportunities for improved treatment outcomes and early detection, supporting market growth.

United States Tuberculosis Treatment Market Overview

Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially spreading to other organs. Tuberculosis treatment involves a prolonged regimen of antibiotics, typically including isoniazid, rifampin, ethambutol, and pyrazinamide. The United States tuberculosis treatment market is driven by rising public health initiatives, diagnostic advancements, and increased focus on multidrug-resistant tuberculosis management.

United States Tuberculosis Treatment Market Growth Drivers

Rising Tuberculosis Incidence to Accelerate Market Growth in the United States

The increasing incidence of tuberculosis is a significant growth driver in the market. According to the Centers for Disease Control and Prevention (CDC), in March 2023, the country reported 9,633 cases of tuberculosis disease, reflecting a 15.6% rise compared to 2022 and an 8.3% increase from 2019. This highlights the urgent need for enhanced diagnostics, effective treatment regimens, and stronger public health responses, ultimately accelerating the growth of the tuberculosis treatment market in the region.

United States Tuberculosis Treatment Market Trends

Some of the notable trends in the market include the introduction of shorter regimens and advancements in drug-resistant tuberculosis therapies.

Introduction of Shorter Regimens Likely to Boost Market Growth

A notable trend in the market is the growing focus on reducing treatment duration. In March 2024, the Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium launched the CRUSH-TB clinical trial to evaluate new drug combinations aimed at reducing treatment time. This advancement is expected to significantly boost market value and therapeutic adoption.

Advancement in Drug-Resistant Tuberculosis Therapies to Elevate the United States Tuberculosis Treatment Market Value

A rising trend in the market is the advancement of therapies targeting drug-resistant TB. Pharmaceutical research has increasingly focused on novel antimicrobials and improved diagnostics to address multidrug-resistant and extensively drug-resistant tuberculosis. This innovation is enhancing treatment efficacy, improving patient outcomes, and expanding opportunities for market growth.

United States Tuberculosis Treatment Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Disease Type

• Active TB
• Latent TB

Market Breakup by Therapy

• First-Line Therapy
• Second-Line Therapy

Market Breakup by Dosage Form

• Tablets
• Capsules
• Injections
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by End User

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

United States Tuberculosis Treatment Market Share

First-Line Therapy Expected to Dominate the Market Share

First-line therapy and second-line therapy are the types of therapies in the market. First-line therapy is expected to hold a substantial the tuberculosis treatment market due to its effectiveness, lower cost, and widespread use in treating drug-sensitive tuberculosis cases. Medications such as isoniazid and rifampin remain the standard approach for initial treatment. Increasing early diagnosis and adherence to treatment protocols further contribute to the dominance of first-line therapy.

United States Tuberculosis Treatment Market Analysis by Region

The market is primarily driven by the West and South regions. The West, with its advanced healthcare infrastructure and higher immigrant population, shows significant market demand. The South, facing a higher disease burden, also contributes notably to market growth through increased public health initiatives and treatment access. These regions are central to addressing tuberculosis effectively.

Leading Players in the United States Tuberculosis Treatment Market

The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Johnson and Johnson Services Inc

Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson is a global healthcare leader actively involved in the market. In July 2024, the company received full approval from the U.S. FDA and the European Commission for Sirturo (bedaquiline), a key treatment for multidrug-resistant tuberculosis and a major advancement in TB care.

Otsuka Pharmaceutical, Inc

Otsuka Pharmaceutical Co., Ltd, headquartered in Tokyo, Japan, is actively involved in tuberculosis treatment research. In March 2024, its U.S. affiliate, Otsuka Pharmaceutical, Inc., based in Princeton, New Jersey, announced promising interim Phase 2b/c trial results for Quabodepistat (QBS), a novel compound potentially reducing tuberculosis treatment duration when combined with delamanid and bedaquiline.

GlaxoSmithKline plc

GlaxoSmithKline plc is a major player involved in tuberculosis treatment in the United States. In May 2024, GSK expanded its strategic collaboration with BioVersys to advance alpibectir (BVL-GSK098), a novel anti-tuberculosis drug candidate. This Phase 2a clinical asset targets multidrug-resistant tuberculosis, addressing a critical public health challenge.

Lupin

Lupin Limited, established in 1968 and headquartered in Mumbai, India, is a global pharmaceutical company actively involved in tuberculosis treatment. In September 2021, Lupin partnered with TB Alliance to manufacture and commercialize pretomanid, part of the BPaL regimen for highly drug-resistant tuberculosis. This collaboration aims to enhance access to advanced TB therapies, including in the United States.

Other key players in the market include Sanofi, Pfizer Inc., Novartis AG, Merck & Co., Inc., Cipla Ltd, and Macleods Pharmaceuticals Ltd

Key Questions Answered in the United States Tuberculosis Treatment Market Report

• What was the United States tuberculosis treatment market value in 2024?
• What is the United States tuberculosis treatment market forecast outlook for 2025-2034?
• What is the market segmentation based on disease type?
• What is the market breakup based on the therapy?
• What is the market breakup based on the dosage form?
• How is the market segmented based on route of administration?
• How is the market divided based on the end user?
• What are the major factors aiding the United States tuberculosis treatment market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major United States tuberculosis treatment market trends?
• Which disease type is expected to dominate the market segment?
• Which therapy is expected to dominate the market segment?
• Which dosage form is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the United States tuberculosis treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.